Trial Profile
Effects of Sitagliptin On Markers of Bone Turnover in Patients With Type 2 Diabetes
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 29 Jun 2010 Results from 9 patients were reported at the 70th Annual Scientific Sessions of the American Diabetes Association.
- 25 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Jan 2010 Planned end date changed from 1 Sep 2009 to 1 Aug 2010 as reported by ClinicalTrials.gov.